1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Neumora Reveals Mid-Stage Data For Fully Funded, Phase III-Ready Depression Drug

Private Biotech Has Raised $650m To Date

 
• By Mandy Jackson

Neumora’s once-daily oral kappa opioid receptor (KOR) antagonist navacaprant succeeded in a Phase II trial and will move into the first of three Phase III studies soon, with a US filing targeted for 2025.

Fear, loneliness, depression, abuse, addiction
Neumora's navacaprant aims to treat anhedonia, an inability to experience pleasure or joy, in depression patients • Source: Shutterstock

Privately held Neumora Therapeutics, Inc. has one well-funded rival in the late-stage development of a kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD), but as the company moves its drug candidate navacaprant (NMRA-140) into Phase III this year, it also has its own deep well of cash to execute its pivotal trials and a slightly different approach to the MDD market than Johnson & Johnson has taken with its Phase III KOR antagonist aticaprant.

Neumora was founded in 2019 to develop precision medicines for neuropsychiatric and neurodegenerative diseases, and came out of stealth mode in 2021 with more than $400m in series A venture...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

More from R&D

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.